Investor Relations

Sonoma Keeps You Informed

Sign up for email alerts to receive Sonoma updates including press releases, filings and special announcements straight to your inbox.

We're sorry, but this form has spam protection that requires JavaScript to be enabled to work correctly. If you'd like to contact us via this form, please enable scripts in your browser and reload the page.

First Name

Last Name

Email Address

Contact Type:

Sign me up for:

All Press Releases

All SEC Filings

10-K & 10-Q Reports

Current Reports

Insider Transactions

Proxy Information

National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced

Aug 15, 2023

View All News

Q1 2024

Quarter Ended Jun 30, 2023

Earnings Release

PDF HTML

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

Fiscal Year Ended Mar 31, 2023

View Filing

Stock Information

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions. The company's products, which are sold throughout the world, have improved outcomes for more than ten million patients globally by reducing infection, itch, pain, scarring and harmful inflammatory responses. Sonoma’s headquarters are in Woodstock, Georgia, with manufacturing operations in Jalisco, Mexico. European marketing and sales are headquartered in Roermond, Netherlands.

Sonoma Investor Presentation May 2023

Download Sonoma Investor Presentation May 2023

Investor Contact Information

Company

Sonoma Pharmaceuticals, Inc.
5445 Conestoga Court
Suite 150
Boulder, CO 80301
T: 800-759-9305
ap@sonomapharma.com